|
KMID : 0043320100330030387
|
|
Archives of Pharmacal Research
2010 Volume.33 No. 3 p.387 ~ p.394
|
|
|
The Protective Effects of Paclitaxel on Platelet Aggregation through the Inhibition of Thromboxane A2 Synthase
|
|
Yun Yeo-Pyo
Lee Jung-Jin
Yu Ji-Yeon
Zhang Wei-Yun
Kim Tack-Joong
Myung Chang-Seon
|
|
|
Abstract
|
|
|
|
Paclitaxel is an anticancer drug used in the treatment of ovarian, breast, head and neck, lung, and prostate cancer. We investigated the anti-platelet activity of paclitaxel in vitro as well as a possible anti-platelet mechanism. Paclitaxel inhibited washed rabbit platelet aggregation induced by collagen in a concentration-dependent manner, with an IC50 of 59.7 ± 3.5. However, it had little effect on platelet aggregation mediated by arachidonic acid, U46619, a thromboxane (TX) A2 mimic, or thrombin, suggesting that paclitaxel may strongly inhibit collagenmediated signal transduction. In accordance with these findings, paclitaxel blocked collageninduced cytosolic calcium mobilization, arachidonic acid liberation, and serotonin secretion. In addition, it inhibited arachidonic acid-mediated platelet aggregation by about 37% by interfering with TXA2 synthase as measured by the formation of arachidonic acid-mediated TXA2 and prostaglandin D2, as well as cyclooxygenase-1 and TXA2 synthase activity assays. Taken together, these results point to a cellular mechanism for the anti-platelet activity of paclitaxel through the inhibition of TXA2 synthase and cytosolic calcium mobilization. This may contribute to the beneficial effects of paclitaxel on the cardiovascular system.
|
|
|
KEYWORD
|
|
|
Paclitaxel, Platelet aggregation, TXA2 synthase, Ca2+ mobilization
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|